Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IMV (IMVIQ)
OTHER OTC:IMVIQ
IMV (IMVIQ) Stock Price & Analysis
356 Followers
IMVIQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $0.28
Previous Close$0.02
Volume3.86K
Average Volume (3M)N/A
Market Cap
$9.61M
Enterprise Value$17.28M
Total Cash (Recent Filing)$21.22M
Total Debt (Recent Filing)$28.90M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 14, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.47
Shares Outstanding11,711,640
10 Day Avg. Volume328
30 Day Avg. VolumeN/A
Standard Deviation0.33
R-Squared0.04
Alpha-0.15
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-508.24
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IMVIQ FAQ
What was IMV’s price range in the past 12 months?
IMV lowest stock price was <$0.01 and its highest was $0.28 in the past 12 months.
What is IMV’s market cap?
Currently, no data Available
When is IMV’s upcoming earnings report date?
IMV’s upcoming earnings report date is Mar 14, 2024 which is 126 days ago.
How were IMV’s earnings last quarter?
Currently, no data Available
Is IMV overvalued?
According to Wall Street analysts IMV’s price is currently Overvalued.
Does IMV pay dividends?
IMV does not currently pay dividends.
What is IMV’s EPS estimate?
IMV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IMV have?
IMV has 11,711,637 shares outstanding.
What happened to IMV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IMV?
Currently, no hedge funds are holding shares in IMVIQ
---
Company Description
IMV
IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
---
IMVIQ Company Deck
---
IMVIQ Earnings Call
Q4 2023
0:00 / 0:00
---
IMVIQ Stock 12 Month Forecast
Average Price Target
―---